Surface Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SURF research report →
Price Chart
About the company
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation.
- CEO
- Lisa McGrath
- IPO
- 2018
- Employees
- 35
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on SURF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $65.08M
- P/E
- -0.91
- PEG
- 0.03
- P/S
- 2.17
- P/B
- 0.64
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -206.23%
- Net Margin
- -217.68%
- ROE
- -61.52%
- ROIC
- -41.40%
Latest fiscal year · YoY change
- Revenue
- $30.00M+1016.5%
- Gross Profit
- $30.00M+1016.5%
- Op Income
- $-61,869,000
- Net Income
- $-65,303,000+17.8%
- EPS
- $-1.17+35.0%
- OCF Growth
- +4.5%
- FCF Growth
- +3.9%
- 52W High
- $1.43
- 52W Low
- $0.56
- 50D MA
- $0.96
- 200D MA
- $0.82
- Beta
- 1.75
- RSI (14)
- 61
- Avg Volume
- 798.15K
No earnings-call transcripts are available for SURF yet.
- Free Float
- 80.2%
- Shares Outstanding
- 60.82M
- Float Shares
- 48.80M
of shares held by institutions
71 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 144.22K | ▲ 59.05K |
| Parametric Portfolio Associates LLC | 17.71K | ▲ 7.61K |
| Amalgamated Financial Corp. | 4.26K | ▲ 4.26K |
Held by 1 ETFs
Biggest fund positions in SURF by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 23 | Sigal Charles Elliott | sell | 113,636 |
| Sep 8, 23 | Sigal Charles Elliott | sell | 45,453 |
| Sep 8, 23 | Adams Chandra | sell | 50,000 |
| Sep 8, 23 | Adams Chandra | sell | 23,884 |
| Sep 8, 23 | RATH HENRY C. | sell | 44,971 |
| Sep 8, 23 | RATH HENRY C. | sell | 150,000 |
| Sep 8, 23 | Palombella Vito J. | sell | 87,212 |
| Sep 8, 23 | Palombella Vito J. | sell | 150,000 |
| Sep 8, 23 | Goater Jeff | sell | 129,222 |
| Sep 8, 23 | FEES JESSICA | sell | 101,915 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SURF coverage
Recent articles, reports, and earnings notes.
No research on SURF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SURF report →Tyra Biosciences: SURF302 Is A Worthwhile Binary Bet
seekingalpha.com · Aug 10
Honeywell Aerospace runway safety technology selected by Aeromexico for intended deployment on more than 100 aircraft
prnewswire.com · Jul 20
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
globenewswire.com · Aug 31
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
businesswire.com · Aug 7
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
globenewswire.com · Aug 2
SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
businesswire.com · Jun 21
Best Penny Stocks To Buy This Week? 3 To Watch Right Now
pennystocks.com · Jun 20
Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences
proactiveinvestors.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.